AAFP backs FDA tentative trans fats determination

AAFP backs FDA tentative trans fats determination

(HealthDay)—The American Academy of Family Physicians (AAFP) has expressed their support for the U.S. Food and Drug Administration's tentative determination regarding partially hydrogenated oils (PHOs) as food additives.

Noting that PHOs have been used in food for many years based on self-determinations that such use is generally safe, Jeffrey J. Cain, M.D., board chair of the AAFP, responded via letter to the FDA's request for comments about the tentative determination regarding PHOs. If the tentative determination is finalized, food manufacturers will no longer be allowed to sell PHOs unless the manufacturer has received FDA approval.

In a literature review, members of the AAFP's Americans in Motion-Healthy Interventions initiative panel found that PHOs contribute to obesity in children and adults, have adverse effects on , increase the risk of , and contribute to insulin resistance.

"The AAFP reviewed the scientific evidence cited and we are pleased to wholeheartedly support the FDA's determination that PHOs are not generally safe for use in food," Cain writes in the letter.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

AAFP to Obama: Family docs key in violence prevention

Jan 25, 2013

(HealthDay)—Family physicians can play a role in addressing and preventing violence in the community, according to a Jan. 17 letter to President Obama from the American Association of Family Physicians ...

IPAs and PHOs viable option for small independent practices

Aug 09, 2013

(HealthDay)—For small and medium-size independent practices, sharing care management and information technology resources with other practices through an independent practice association (IPA) or physician-hospital ...

FDA encourages opioid prescribers to pursue training

Mar 12, 2013

(HealthDay)—Prescribers of extended-release/long-acting (ER/LA) opioid analgesics are encouraged to participate in continuing medical education (CME) provided by manufacturers of these analgesics, according ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments